Shyamakant Giri has been named the new Chief Executive Officer of Gland Pharma, a prominent player in the pharmaceutical industry. With over two decades of experience across healthcare and pharmaceuticals, Shyamakant Giri is set to bring his leadership expertise to the company, guiding it into its next phase of growth. His appointment marks a significant shift for Gland Pharma, where the current CEO, Srinivas Sadu, will transition into the role of executive chairman to support the company’s future initiatives.
Shyamakant Giri currently serves as the President of India Business and Emerging Markets at Amneal Pharmaceuticals, where he oversees commercial activities across key markets. His background spans leadership roles in major organizations such as Rivaara Labs and Abbott India, where he contributed to the growth of healthcare solutions across diverse markets, including Asia, Africa, and Latin America. His experience in managing both emerging and established markets positions him well for his new role at Gland Pharma.
Before joining Amneal, Shyamakant Giri held leadership positions at Rivaara Labs and spent almost two decades at Abbott in various roles. He has also been instrumental in creating new business ventures and improving operational efficiency in organizations he has been part of. Shyamakant Giri’s educational qualifications include a Master’s in Marketing Management from Jamnalal Bajaj Institute of Management Studies, a Master’s in Organic Chemistry from Mumbai University, and executive programs from INSEAD, Singapore, and IIM Ahmedabad.
As Shyamakant Giri steps into his new role at Gland Pharma, the company looks forward to leveraging his expertise in healthcare and pharmaceuticals to drive growth and innovation across its global operations.
